FLT3 and acute myeloid leukemia: Second-generation FLT3 inhibitors, such as gilteritinib and quizartinib, have demonstrated superior CR/CRi rates and improved overall survival (OS) compared with standard salvage regimens in patients with R/R AML and an FLT3 mutation [12,13].